| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 727.10M | 757.10M | 802.50M | 743.60M | 615.80M | 598.00M |
| Gross Profit | 100.50M | 109.30M | 108.10M | 269.70M | 225.70M | 186.90M |
| EBITDA | 176.80M | 124.00M | 201.70M | 186.60M | 167.70M | 97.00M |
| Net Income | 28.40M | 20.00M | 85.60M | 73.70M | 59.50M | 400.00K |
Balance Sheet | ||||||
| Total Assets | 1.05B | 1.07B | 1.14B | 1.17B | 1.07B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 20.20M | 19.10M | 45.20M | 37.20M | 39.30M | 30.70M |
| Total Debt | 190.50M | 150.90M | 96.90M | 136.60M | 156.20M | 128.80M |
| Total Liabilities | 406.70M | 397.50M | 344.40M | 385.70M | 384.40M | 428.60M |
| Stockholders Equity | 639.40M | 668.10M | 790.80M | 780.90M | 684.70M | 680.50M |
Cash Flow | ||||||
| Free Cash Flow | 70.40M | 82.50M | 109.20M | 70.10M | 87.10M | 74.50M |
| Operating Cash Flow | 146.70M | 152.60M | 191.60M | 137.10M | 139.10M | 134.40M |
| Investing Cash Flow | -64.20M | -112.80M | -71.20M | -62.30M | -104.80M | -124.70M |
| Financing Cash Flow | -74.40M | -67.60M | -110.20M | -82.80M | -30.30M | -6.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £5.79B | 25.13 | 23.79% | 1.29% | -0.32% | -3.96% | |
74 Outperform | £7.42B | 24.23 | 17.68% | 1.24% | -1.97% | 40.55% | |
71 Outperform | £5.18B | 31.85 | 14.19% | 2.35% | 0.10% | -15.33% | |
66 Neutral | £1.70B | 69.38 | 18.87% | 0.57% | 14.88% | 45.73% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
60 Neutral | £559.38M | 20.35 | 8.04% | 5.14% | -7.30% | -59.71% | |
55 Neutral | £1.07B | 38.73 | 4.10% | 3.05% | -6.95% | -52.08% |
Bodycote plc has announced a continuation of its share buyback program, purchasing 36,188 of its ordinary shares at a volume-weighted average price of 635.87 pence per share. This move, part of an extended program, aims to cancel the repurchased shares, reducing the total number of shares in issue to 175,699,513, thereby potentially increasing shareholder value and consolidating its market position.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £708.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the continuation of its share buyback program, purchasing 36,248 ordinary shares at a volume-weighted average price of 635.77 pence per share. This move is part of an extended program aimed at reducing the number of shares in circulation, thereby potentially increasing the value of remaining shares and strengthening the company’s market position.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £708.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced a transaction involving the repurchase of its own shares as part of an extended share buyback programme. The company purchased 36,940 ordinary shares at a volume-weighted average price of 627.26 pence per share, with plans to cancel these shares, reducing the total number of shares in issue to 176,984,103. This move is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.